JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $109
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Biomarin Pharmaceutical but lowers the price target from $110 to $109.
October 30, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains an Overweight rating on Biomarin Pharmaceutical, indicating continued confidence in the stock, but slightly lowers the price target from $110 to $109.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target indicates a minor adjustment in expectations. This is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100